Literature DB >> 22537476

Time to effective antibiotic administration in adult patients with septic shock: a descriptive analysis.

Zahra Kanji1, Carla Dumaresque.   

Abstract

OBJECTIVE: To determine the median time to antibiotic administration following the onset of septic shock at our institution as well as the appropriateness of empiric therapy, sources of delay in antibiotic administration and the effect of delays on survival. RESEARCH
METHODOLOGY: Retrospective health record review of 55 patients with septic shock admitted to the intensive care unit (ICU) between July 1, 2008 and December 31, 2009.
SETTING: Nine-bed adult medical-surgical ICU within a 300-bed community acute care hospital. MAIN OUTCOME MEASURES: Median time to antibiotic administration, appropriateness of empiric therapy, sources of delay in antibiotic administration.
RESULTS: The median (min,max) time to the initiation of antibiotics was determined to be 1.7 (0,31) hours. Only 34% (19/55) of patients received antibiotics within the recommended one hour. Empiric antibiotic therapy was determined to be appropriate in 91% (50/55) of patients. The median (min,max) time to administration of effective antibiotic therapy tended to be faster in the emergency room [1.1 (0,16) hours] compared to the ICU [2.3 (0,13)].
CONCLUSION: The median time to antibiotic administration at our institution following the onset of septic shock was longer than the evidence-based guideline recommendations of within one hour.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22537476     DOI: 10.1016/j.iccn.2012.01.009

Source DB:  PubMed          Journal:  Intensive Crit Care Nurs        ISSN: 0964-3397            Impact factor:   3.072


  1 in total

1.  Utilization of Pharmacist Responders as a Component of a Multidisciplinary Sepsis Bundle.

Authors:  Jeremy D Flynn; Kevin W McConeghy; Alexander H Flannery; Melissa Nestor; Pam Branson; Kevin W Hatton
Journal:  Ann Pharmacother       Date:  2014-06-05       Impact factor: 3.154

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.